NCT00229593 (NES-1) is a Phase 1 clinical trial of Nestorone gel in Contraception, sponsored by University of Washington.

Who is sponsoring NCT00229593?

NCT00229593 is sponsored by University of Washington.

What drugs are being tested in NCT00229593?

Interventions in NCT00229593: Nestorone gel, Testosterone Gel.

What condition does NCT00229593 study?

NCT00229593 studies Contraception.

Is NCT00229593 still recruiting?

NCT00229593 is currently completed. Last updated 3 December 2014.

Last reviewed 2014-12-03 · How we verify

NCT00229593: NES-1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized, Open Label Clinical Trial to Evaluate if Nestorone Gel Has Gonadotropin Suppressive Activity and if Nestorone in Combination With Testosterone Will Have an Additive Effect on Gonadotropin Suppression When Applied Transdermally in Healthy Men

Completed Phase 1 Last updated 3 December 2014

What this trial tests

Phase 1 trial testing Nestorone gel in Contraception in 140 participants. Completed in 1 January 2007.

Timeline

1 September 2005

Primary endpoint
1 January 2007

1 January 2007

Quick facts

Lead sponsor	University of Washington
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	140
Start date	1 September 2005
Primary completion	1 January 2007
Estimated completion	1 January 2007
Sites	2 locations across United States

Drugs / interventions tested

Nestorone gel — full drug profile →
Testosterone Gel

Conditions studied

Contraception — all drugs for Contraception →

Sponsor

University of Washington

Who can join

Adults 18 to 50, male only, with Contraception. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

- To determine the gonadotropin suppressive activity of Nestorone (NES) Gel at two doses and T gel at one dose alone or in combination over a 3-week period. Serum levels of gonadotropins will be assessed in all subjects.
Time frame: 3 weeks

Sponsor's own description

The purpose of this study is to determine the usefulness of two transdermal gels to be used in the future development for a male contraceptive.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Contraception

Currently open trials in the same condition.

NCT07365904 — Investigating Ovulation Inhibition for Use as a Contraceptive · Phase 2 · recruiting
NCT07437495 — Women's Knowledge of Contraception During the Postpartum Period · active not recruiting
NCT06823037 — Hormonal Contraception Access Through Pharmacist Prescribing Implementation · NA · recruiting
NCT07326007 — Verbal Analgesia Versus Standard Technique for Pain Control During Copper T380A Intrauterine Device Insertion in Women W · NA · recruiting
NCT05910580 — Improving Alcohol and Substance Use Care Access, Outcome, Equity During the Reproductive Years · NA · recruiting

Other University of Washington trials

Trials by the same sponsor.

NCT07430852 — Inherited and Environmental Risks Acting on Body Weight · NA · not yet recruiting
NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc · Phase 2 · not yet recruiting
NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn · NA · not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00229593 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Washington
Last refreshed: 3 December 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00229593.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing